Cancer Diagnostic Markers Top Celera's Agenda Following Sequencing Coup
This article was originally published in The Gray Sheet
Executive Summary
Colon, pancreatic and breast cancers are initial disease areas for which Celera Genomics plans to develop diagnostic markers. In support of the effort, Celera will expand its high-throughput screening capability with the construction of a proteomics facility at the firm's Rockville, Maryland headquarters this spring.
You may also be interested in...
Exact Sciences' $56 Mil. IPO Readies Firm For Colorectal Cancer Screen Trial
Exact Sciences will use about $19 mil. of its $56 mil. initial public offering to fund a 5,300-patient, 40-center clinical trial evaluating genomics-based diagnostics to screen for colorectal cancer.
PE Biosystems Eyeing Spin-out Of Expanded Molecular Diagnostic Business
PE Corp. is looking to leverage the capabilities of its two component business units, PE Biosystems and Celera Genomics, to increase the company's presence in the molecular diagnostics field, most likely through a spin-out of the new operation.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.